Recombinant Human Papilloma Virus type 11 L1 protein (VLP) (DAGF-228)

Human Papilloma Virus type 11 L1 protein (VLP), recombinant protein from E. coli

Nature
Recombinant
Tag/Conjugate
Unconjugated
Molecular Weight
50 kDa
Alternative Names
HPV 11 L1; L1; Major capsid protein L1
Procedure
None
Purity
> 95%(SDS-PAGE)
Format
Liquid
Concentration
Batch dependent - please inquire should you have specific requirements.
Buffer
500 mM Histidine 100mM NaCl 0.02%Tween80(pH6.0)
Preservative
None
Storage
Store at -70°C, avoid repeat freeze/thaw cycles
Antigen Description
Human papillomavirus (HPV) is a DNA virus from the papillomavirus family that is capable of infecting humans. Like all papillomaviruses, HPVs establish productive infections only in keratinocytes of the skin or mucous membranes. L1 is a major capsid protein of human papilloma virus. Infection with specific types of HPV has been associated with an increased risk of developing cervical neoplasia. Does not bind DNA.
Keywords
HPV 11 L1; L1; Major capsid protein L1

Citations


Have you cited DAGF-228 in a publication? Let us know and earn a reward for your research.

Related Products


Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Co-infection between genotypes of the human papillomavirus andChlamydia trachomatisin Mexican women

INTERNATIONAL JOURNAL OF STD & AIDS

Authors: Escarcega-Tame, Marco A.; Lopez-Hurtado, Marcela; Escobedo-Guerra, Marcos R.; Reyes-Maldonado, Elba; Castro-Escarpulli, Graciela; Guerra-Infante, Fernando M.

Not all human papillomavirus (HPV) infections develop into cervical cancer (CC), so it is proposed that other factors may influence this, such as co-infection withChlamydia trachomatis(CT). To identify the prevalence of co-infection, we included 189 women with suspicion of HPV. Viral typing was performed by carrying out the Roche HP Linear Array test, while CT detection was performed with the COBAS (R) TaqMan (R) 48 kit from Roche. Of the 189 women only 184 had an infection with HPV, CT or both: 56.6% were positive for one or several HPV genotypes, and 67.7% for CT. Clinical data showed an association between HPV and CIN I (n = 22; RR = 2.43; 95% CI 1.72-3.43, p < 0.05). CT infection was only associated with cervicitis (n = 40; RR = 1.73; 95% CI 1.34-2.23, p < 0.05). The CT-HPV co-infection rate was 28%. Co-infection revealed an association with CIN I (n = 31, RR= 3.33; 95% CI 2.08-5.34 p < 0.05), CIN III (n = 7; RR = 2.57; 95% CI 1.53-4.31, p < 0.05); and a significant risk of 2.3 (95% CI 1.08-4.90) times higher to develop CC; nevertheless, this risk was not statistically significant. CT/HPV co-infection was associated with the development of a high-grade lesion (CIN III) as well as an important risk for developing CC.

Comparative cohort study of volumetric modulated arc therapy for squamous cell cancer of unknown primary in the head and neck-Involved neck only versus mucosal irradiation

CLINICAL OTOLARYNGOLOGY

Authors: Poon, Wai-Yan; Thomson, Maureen; McLoone, Philip; Wilson, Christina; Crosbie, Robin; Schipani, Stefano; Grose, Derek; James, Allan; Lamb, Carolynn; Rizwanullah, Mohammed; Campbell, Frances; Easton, Fiona; Paterson, Claire

Objectives Target volumes for irradiation remain ill-defined for squamous cell cancer of unknown primary in the head and neck (SCCUP). The aim of this study was to compare involved neck only (INO) radiotherapy (RT) with irradiating involved neck plus potential mucosal primary sites and contralateral neck (MUC) in patients diagnosed and treated with modern diagnostics and techniques. Design This is a retrospective cohort study. Patients with a diagnosis of SCCUP with unilateral neck disease were included. Results Thirty patients were identified. All underwent FDG PET-CT. 47% of patients had HPV-positive SCC. 20 patients received RT to INO, 10 patients to MUC, all with volumetric modulated arc therapy (VMAT). A significantly lower dose for each organ at risk was delivered in INO-treated patients, with mean dose to contralateral parotid gland 57% less. The proportion of patients with late grade 2 or worse xerostomia was higher in MUC patients. The incidence of grade 2-3 mucositis (89% vs 45%) and grade 3 or worse dysphagia (50% vs 10%) was higher in MUC patients. Median follow-up was 31 months. No mucosal primaries emerged. Progression-free survival at 2 years was 74.7% for INO patients, 70% in the MUC group. Overall survival at 2 years was 79.7% in the INO group and 70% in the MUC patients. Conclusion INO radiotherapy for patients with SCCUP of the head and neck is a safe treatment strategy resulting in clinically significant lower RT doses to OARS. Acute and late toxicities are reduced without detriment to patient survival.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket